Charlie Galvin is General Manager for the UK, Ireland, and Canada at Amicus Therapeutics.
Prior to this, Charlie gained a breadth of pharmaceutical experience in market access, policy, commercial management, and marketing roles at Amgen and then Pfizer. Charlie is passionate about making the UK a world leader in science and innovation and that this translates into making a meaningful difference for patients.
Championing this agenda is her mission in her cross-industry roles as chair of the Rare Disease Industry Group, member of the ABPI Board and an industry representative on the NICE methods review working group.